Recently, GLP-1 receptor agonists, have been confirmed to reduce all-cause mortality and worsening kidney function in patients with type 2 diabetes and ongoing clinical trials have shown promising results in patients with non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and are being explored in Alzheimer’s disease suggesting additional potential indications besides T2D and obesity for mechanisms that potentiate activation of GLP1 receptor (35–38). Here, GLP1R is linked to type 2 diabetes mellitus.